Table 2.
Comparison Between the Two Groups (CVA Gain ≥15 Letters Versus <15 Letters) in Terms of Demographic and Clinical Features
| Features | CVA Gain ≥15 Letters (n = 60) | CVA Gain <15 Letters (n = 61) | Total Set (n = 121) | P Value |
|---|---|---|---|---|
| Age, years ± SD | 67 ± 15 | 67 ± 14 | 67 ± 15 | 1.00 |
| Sex | 0.17 | |||
| Female, n (%) | 47 (78) | 41 (67) | 88 (73) | |
| Male, n (%) | 13 (22) | 20 (33) | 33 (27) | |
| Baseline CVA, letters ± SD | 42 ± 15 | 59 ± 10 | 50 ± 16 | <0.0001 |
| MH size, µm ± SD | 394 ± 183 | 293 ± 131 | 343 ± 167 | 0.0008 |
| MH duration, weeks ± SD | 11 ± 12 | 10 ± 7 | 10 ± 10 | 0.58 |
| Pseudophakic, n (%) | 15 (25) | 7 (12) | 22 (18) | 0.05 |
| Phacovitrectomy, n (%) | 0 (0) | 1 (2) | 1 (2) | 0.32 |
| CVA at 6 months, letters ± SD | 70 ± 9 | 62 ± 12 | 66 ± 12 | <0.0001 |
| Stage of MH | 0.53 | |||
| Stage 2, n (%) | 10 (17) | 9 (15) | 19 (16) | |
| Stage 3, n (%) | 35 (58) | 39 (64) | 74 (61) | |
| Stage 4, n (%) | 15 (25) | 13 (21) | 28 (23) | |
| Surgery procedure | ||||
| Vitrectomy with ILM peeling, n (%) | 60 (100) | 61 (100) | 121 (100) | 0.99 |
| Tamponade used | 0.98 | |||
| SF6, n (%) | 53 (88) | 54 (89) | 107 (88) | |
| C3F8, n (%) | 7 (12) | 7 (12) | 14 (12) | |
| Dye used | 0.11 | |||
| ICG, n (%) | 43 (72) | 51 (84) | 94 (78) | |
| TB, n (%) | 17 (28) | 10 (16) | 27 (22) |
MH, macular hole; ILM, internal limiting membrane; CVA, corrected visual acuity; ICG, indocyanine green; TB, trypan blue; SD, standard deviation.